Nature of Business and Basis of Presentation (Details) - USD ($) $ / shares in Units, $ in Thousands				1 Months Ended		12 Months Ended
	Dec. 10, 2021	Nov. 19, 2020	Oct. 27, 2020	Jan. 31, 2022	Jul. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements
Upfront payment received					$ 15,000	$ 15,000
Net loss						(101,320)	$ (68,800)
Accumulated deficit						$ 264,256	$ 162,936
Eli Lilly | Subsequent Event
Organization Consolidation And Presentation Of Financial Statements
Upfront payment received				$ 300,000
IPO
Organization Consolidation And Presentation Of Financial Statements
Stock issued during the period shares new issues shares (in shares)			7,500,000
Sale of stock issue price per share (in dollars per share)			$ 16.00
Sale of stock consideration received on the transaction			$ 107,900
IPO | Common Stock
Organization Consolidation And Presentation Of Financial Statements
Stock issued during the period shares new issues shares (in shares)			7,500,000
Sale of stock issue price per share (in dollars per share)			$ 16.00
Sale of stock consideration received on the transaction			$ 107,900
Over-Allotment Option
Organization Consolidation And Presentation Of Financial Statements
Stock issued during the period shares new issues shares (in shares)		951,837
Sale of stock issue price per share (in dollars per share)		$ 16.00
Sale of stock consideration received on the transaction		$ 14,200
Over-Allotment Option | Common Stock
Organization Consolidation And Presentation Of Financial Statements
Stock issued during the period shares new issues shares (in shares)		951,837
Sale of stock issue price per share (in dollars per share)		$ 16.00
Sale of stock consideration received on the transaction		$ 14,200
Share Purchase Agreement | Eli Lilly
Organization Consolidation And Presentation Of Financial Statements
Sale of stock issue price per share (in dollars per share)	$ 20.00
Sale of stock consideration received on the transaction	$ 80,000
Sale of stock, number of shares issued in transaction (in shares)	4,000,000
Share Purchase Agreement | Eli Lilly | Common Stock
Organization Consolidation And Presentation Of Financial Statements
Sale of stock consideration received on the transaction	$ 42,200